When switching a patient from Mounjaro (tirzepatide) 15 mg weekly to Zepbound (semaglutide), should the 15 mg weekly dose be continued?

You Cannot Simply Keep the 15 mg Dose When Switching from Mounjaro to Zepbound

These are two completely different medications with different active ingredients, different mechanisms of action, and non-interchangeable dosing schedules—you must restart the titration protocol from the beginning.

Critical Clarification: Mounjaro ≠ Zepbound

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist, while Zepbound is actually the brand name for tirzepatide used for obesity treatment—they contain the same active ingredient 1. If you're asking about switching from Mounjaro 15 mg to semaglutide (Wegovy/Ozempic), which appears to be the actual clinical question based on the context, then the answer is definitively NO—you cannot maintain the 15 mg dose.

If Switching from Tirzepatide 15 mg to Semaglutide: Start Fresh

When transitioning from tirzepatide (Mounjaro) 15 mg to semaglutide (Wegovy/Ozempic), you must initiate semaglutide at its standard starting dose of 0.25 mg weekly and follow the FDA-approved titration schedule 2.

Semaglutide Titration Protocol:

• Week 1-4: 0.25 mg once weekly
• Week 5-8: 0.5 mg once weekly
• Week 9-12: 1.0 mg once weekly (for diabetes indication)
• Week 13-16: 1.7 mg once weekly (if using for obesity)
• Week 17+: 2.4 mg once weekly (maximum dose for obesity) 2, 3

Why You Cannot Skip Titration:

Gastrointestinal tolerability is dose-dependent and medication-specific. Even though the patient tolerated tirzepatide 15 mg, semaglutide has different pharmacokinetics (half-life ~7 days vs ~5 days for tirzepatide) and receptor binding profiles 4. The most common adverse effects—nausea, vomiting, diarrhea, and constipation—occur most frequently during dose escalation and can lead to treatment discontinuation if titration is too rapid 4, 3.

The 0.25 mg starting dose is specifically designed for treatment initiation and gastrointestinal adaptation, not for glycemic control 2. Skipping this titration increases the risk of severe gastrointestinal adverse events that could compromise treatment adherence.

Comparative Efficacy Context

While tirzepatide 15 mg demonstrates superior weight loss compared to semaglutide 2.4 mg (mean difference of approximately 5-6% additional weight loss) 5, 6, 7, this does not justify dose equivalency or accelerated titration. The patient switching from tirzepatide 15 mg should expect:

• Tirzepatide 15 mg: ~22.5% weight loss at 72 weeks 4
• Semaglutide 2.4 mg: ~15-17% weight loss at 68 weeks 4

However, individual response varies significantly 8, 9. Some patients who are non-responders to tirzepatide may paradoxically respond better to semaglutide, particularly those with markedly elevated insulin resistance (HOMA-IR ≥4-5) 8.

Clinical Algorithm for the Switch

1. Discontinue tirzepatide (last dose given on scheduled day)
2. Wait 4-7 days before initiating semaglutide (allows washout given tirzepatide's ~5-day half-life)
3. Start semaglutide 0.25 mg weekly regardless of prior tirzepatide dose
4. Escalate every 4 weeks as tolerated per FDA protocol
5. Monitor for gastrointestinal symptoms at each dose increase
6. Assess weight loss response at 16 weeks on maintenance dose (should achieve ≥4% weight loss; if not, consider discontinuation) 3

Common Pitfalls to Avoid

• Never assume dose equivalency between different GLP-1 receptor agonists—there is no validated conversion table
• Do not accelerate titration even if the patient "did fine on high-dose tirzepatide"—different medications require different adaptation periods
• Watch for early warning signs of non-response: persistent hyperphagia during the first 8-12 weeks may predict poor overall response 8
• Counsel patients on realistic expectations: switching from tirzepatide to semaglutide may result in less total weight loss, though individual responses vary 5, 6

Special Considerations

No renal dose adjustments are required for semaglutide across all stages of chronic kidney disease, including dialysis 2, 10. This represents an advantage over some other glucose-lowering agents.

If the patient has type 2 diabetes with established cardiovascular disease, semaglutide 2.4 mg offers proven cardiovascular risk reduction (20% reduction in 3-point MACE) 4, which may influence the decision to switch despite potentially lower weight loss efficacy compared to tirzepatide.